HUE058156T2 - Helyettesített triazolok és ezekkel kapcsolatos eljárások - Google Patents

Helyettesített triazolok és ezekkel kapcsolatos eljárások

Info

Publication number
HUE058156T2
HUE058156T2 HUE16703250A HUE16703250A HUE058156T2 HU E058156 T2 HUE058156 T2 HU E058156T2 HU E16703250 A HUE16703250 A HU E16703250A HU E16703250 A HUE16703250 A HU E16703250A HU E058156 T2 HUE058156 T2 HU E058156T2
Authority
HU
Hungary
Prior art keywords
processes related
substituted triazoles
triazoles
substituted
processes
Prior art date
Application number
HUE16703250A
Other languages
English (en)
Hungarian (hu)
Inventor
John Williams
Deborah Slee
Manisha Moorjani
Neil Ashweek
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of HUE058156T2 publication Critical patent/HUE058156T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE16703250A 2015-01-30 2016-01-29 Helyettesített triazolok és ezekkel kapcsolatos eljárások HUE058156T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562110415P 2015-01-30 2015-01-30
US201562259314P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
HUE058156T2 true HUE058156T2 (hu) 2022-07-28

Family

ID=55305123

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16703250A HUE058156T2 (hu) 2015-01-30 2016-01-29 Helyettesített triazolok és ezekkel kapcsolatos eljárások

Country Status (22)

Country Link
US (4) US9718789B2 (enExample)
EP (1) EP3250563B1 (enExample)
JP (1) JP6728198B2 (enExample)
KR (1) KR102575601B1 (enExample)
CN (1) CN107406420B (enExample)
AU (1) AU2016211292B2 (enExample)
BR (1) BR112017016488A2 (enExample)
CA (1) CA2975474C (enExample)
CY (1) CY1125082T1 (enExample)
DK (1) DK3250563T3 (enExample)
ES (1) ES2905878T3 (enExample)
HR (1) HRP20220327T1 (enExample)
HU (1) HUE058156T2 (enExample)
IL (1) IL253705B (enExample)
LT (1) LT3250563T (enExample)
MX (1) MX378932B (enExample)
PL (1) PL3250563T3 (enExample)
PT (1) PT3250563T (enExample)
RS (1) RS62862B1 (enExample)
RU (1) RU2718049C2 (enExample)
SI (1) SI3250563T1 (enExample)
WO (1) WO2016123533A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
ES2693052T3 (es) 2014-09-15 2018-12-07 Idorsia Pharmaceuticals Ltd Compuestos de triazol como bloqueantes de los canales de calcio de tipo T
PT3250563T (pt) 2015-01-30 2022-02-09 Neurocrine Biosciences Inc Triazois substituídos e métodos relacionados aos mesmos
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
US12570612B2 (en) 2019-10-11 2026-03-10 Chengdu Mfs Pharma. Co., Ltd. Substituted nitrogen heterocyclic compound and anesthetic effect thereof
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
CN121378238B (zh) * 2025-12-23 2026-03-31 蚌埠医科大学 一种芳基烷基唑类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) * 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
TW513301B (en) * 1999-03-01 2002-12-11 Novartis Ag Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
PT3250563T (pt) 2015-01-30 2022-02-09 Neurocrine Biosciences Inc Triazois substituídos e métodos relacionados aos mesmos

Also Published As

Publication number Publication date
RS62862B1 (sr) 2022-02-28
JP6728198B2 (ja) 2020-07-22
US10138214B2 (en) 2018-11-27
US20190169137A1 (en) 2019-06-06
CN107406420A (zh) 2017-11-28
EP3250563A1 (en) 2017-12-06
KR102575601B1 (ko) 2023-09-05
CY1125082T1 (el) 2023-06-09
CN107406420B (zh) 2020-11-06
AU2016211292A1 (en) 2017-08-24
IL253705B (en) 2020-09-30
IL253705A0 (en) 2017-09-28
WO2016123533A1 (en) 2016-08-04
MX2017009824A (es) 2017-11-02
US11021449B2 (en) 2021-06-01
CA2975474C (en) 2023-06-13
US20200399229A1 (en) 2020-12-24
LT3250563T (lt) 2022-04-11
PL3250563T3 (pl) 2022-05-02
PT3250563T (pt) 2022-02-09
KR20170106470A (ko) 2017-09-20
US20170349558A1 (en) 2017-12-07
ES2905878T3 (es) 2022-04-12
AU2016211292B2 (en) 2020-05-07
EP3250563B1 (en) 2022-01-12
RU2017130474A (ru) 2019-02-28
US20160221968A1 (en) 2016-08-04
BR112017016488A2 (pt) 2018-04-10
US10738017B2 (en) 2020-08-11
US9718789B2 (en) 2017-08-01
SI3250563T1 (sl) 2022-04-29
NZ734260A (en) 2024-01-26
RU2017130474A3 (enExample) 2019-06-11
JP2018503661A (ja) 2018-02-08
RU2718049C2 (ru) 2020-03-30
DK3250563T3 (da) 2022-01-31
MX378932B (es) 2025-03-10
CA2975474A1 (en) 2016-08-04
HRP20220327T1 (hr) 2022-05-13

Similar Documents

Publication Publication Date Title
NO2025003I1 (no) Fidanacogene elaparvovec
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3305229A4 (en) MEDICAL MANIPULATOR
HUE046509T2 (hu) Új vegyület és eljárás
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
DK3394281T3 (da) Gærcelle
EP3362581A4 (en) ALUMINUM IRON ZIRCONIUM ALLOYS
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3270930T3 (da) Præeklampsi
EP3381654A4 (en) Liquid blow molding method
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
EP3308781A4 (en) BLOOD PRESSURE CENTER
DE112016003293A5 (de) Feuerlöscher
DE112015006486A5 (de) Inkubationsrinne
DE112017004089A5 (de) Al-Gusslegierung
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
EP3384016A4 (en) MANIPULATED PHAGEMIDES
EP3438306A4 (en) NI-FE-CR ALLOY
DE102015206660A8 (de) Plattenaufteilanlage
DE112017006468A5 (de) Al-gusslegierung